Of these 25 patients, the three with NTRK1/2/3 rearranged solid tumors experienced an objective response rate of 100% and included NSCLC, colorectal, and glioneural tumors [1]. This evidence concerns the gene NTRK1 and non-small cell lung carcinoma.